Figure 3. The prognostic signature associated with CRFGs. (A) Differential expression of 15 potentially prognostic CRFGs in LUAD samples and the normal samples. (B) Mutation landscape map of potentially prognostic CRFGs, showing SNV and genomic mutation types. (C, D) Prognostic signature established by LASSO Cox regression analysis. (E) Risk score distribution, patient survival status and CRFGs expression profile calculated by the prognostic signature. (F) Survival curves of LUAD patients in low- and high-risk groups. (G) ROC curves of the prognostic signature at 1, 3, and 5 years. *P < 0.05, **P < 0.01.